Lab On Chip Market Report Evaluates Growth Drivers, Challenges And Market Dynamics - openPR.com

The Lab on Chip market is experiencing rapid growth driven by multiple factors. From a technological perspective, continuous advancements in microfluidic chip technology provide strong technical suppo... Read original →

Advancements in microfluidic chips are catalyzing a convergence between semiconductor manufacturing and biosensing. Foundries must now refine MEMS processes, while downstream diagnostic firms integrate AI to enhance analytical accuracy. Tightening EU/US medical export controls—combined with supply chain concentration in Taiwan, China and South Korea—have sharply raised compliance costs, exposing SMEs to disruption risks. Incumbents like Thermo Fisher and Roche leverage post-pandemic demand by vertically integrating chip design with proprietary reagents, whereas Asian players such as BGI pursue low-cost POCT models for mass-market penetration. Over the next 18 months, ISO/TC 276’s standardization efforts will reduce technical fragmentation, yet geopolitical friction may splinter the market: North America prioritizing FDA-compliant closed systems, Asia favoring rapid commercial iteration. The ultimate winners will be cross-disciplinary firms mastering both semiconductor yield control and bio-compatibility validation.